PNH is a rare, chronic, life-threatening disease affecting the complement cascade, leading to uncontrolled terminal complement activation.^3,5-9

Uncontrolled terminal complement activation leads to life-threatening consequences such as IVH, thromboembolic events, renal impairment and pulmonary hypertension.^10-12 If PNH is left untreated, it can lead to early mortality.^5,13

ULTOMIRIS^® targets uncontrolled terminal complement activity and delivers immediate, complete and sustained C5 inhibition.^1,2,4 For more details, please visit our dedicated Mechanism of Action page below.

ULTOMIRIS^® is contraindicated in patients who have not been vaccinated against Neisseria meningitidis. If a patient initiates ULTOMIRIS^® treatment less than 2 weeks after receiving a meningococcal vaccine, appropriate prophylactic antibiotics should be administered until two weeks after the vaccination.¹

ULTOMIRIS^® is also contraindicated in patients with hypersensitivity to the active substance or any excipients within the formulation.¹

For further information, please visit our dedicated Dosing and Administration page.. 

The efficacy and safety of ULTOMIRIS^® were evaluated in adults and paediatrics in three Phase 3 trials.^2,4,14 More information on how ULTOMIRIS^® was studied can be found below.

Detailed information on the efficacy of ULTOMIRIS^® is available below.

With ULTOMIRIS^®, treatment can be kept on track with a well-established safety profile.^1,4 Further details about the safety of ULTOMIRIS^® can be accessed on the page beneath.

Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion, AstraZeneca Rare Disease by contacting: https://contactazmedical.astrazeneca.com/